Dutch company to work on bird flu vaccine
18 October 2005, AMSTERDAM — Akzo Nobel is working on a human vaccine against the deadly H5N1 strain of the avian flu virus.
18 October 2005
AMSTERDAM — Akzo Nobel is working on a human vaccine against the deadly H5N1 strain of the avian flu virus.
The Dutch-based company's Nobilon biotechnology business recently received European approval to begin producing human influenza vaccines for use in clinical trials.
The approval means that Nobilon— which was set up by Akzo Nobel in 2003 to develop and commercialise human vaccines — is now licensed to manufacture flu vaccines to be used in clinical testing, Akzo Nobel said on Tuesday.
The first trials are scheduled to start in 2006. Clinical trials for the H5N1 vaccine will also be scheduled for next year.
"The current situation in Europe highlights the urgent need for a human vaccine against this potentially lethal infection," said Toon Wilderbeek, Akzo Nobel’s Board Member responsible for Pharma.
The discovery of the H5N1 strain among wild birds in Turkey last week has given rise to fears it could spread across Europe. Romania is also culling birds are a form of avian flu was found there.
Bird flu has been detected in Greece but it has yet to be announced whether it is the strain that is potentially dangerous to humans.
"We are active on a number of fronts regarding the production of human and animal vaccines to counter this particular threat and the combined expertise we have throughout the company is proving invaluable," he added.
[Copyright Expatica News + ANP 2005]
Subject: Dutch news